Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Quach, H; Joshua, D; Ho, J; Szer, J; Spencer, A; Harrison, SJ; Mollee, P; Roberts, AW; Horvath, N; Talulikar, D; To, B; Zannettino, A; Brown, R; Catley, L; Augustson, B; Jaksic, W; Gibson, J; Prince, HM

Author(s): Quach, H; Joshua, D; Ho, J; Szer, J; Spencer, A; Harrison, SJ; Mollee, P; Roberts, AW; Horvath, N; Talulikar, D; To, B; Zannettino, A; Brown, R; Catley, L; Augustson, B; Jaksic, W; Gibson, J; Prince, HM;
Details: Publication Year 2015-01,Volume 45,Issue #1,Page 94-105
Journal Title: Intern Med J
Publication Type: Journal Article
Abstract: The survival of patients with multiple myeloma (MM) has improved substantially since the introduction in the late 1980s of high-dose chemotherapy (HDT) supported by autologous stem cell transplantation (ASCT). Further improvements have been observed following the availability of immunomodulatory drugs (IMiD) such as thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib. Here, we summarise the recommendations of the Medical Scientific Advisory Group to the Myeloma Foundation of Australia for patients considered suitable for HDT + ASCT as part of initial therapy. These recommendations incorporate the various phases of treatment: induction, HDT conditioning and maintenance therapy.
Publisher: Wiley
Research Division(s): Cancer And Haematology
PubMed ID: 25582938
Publisher's Version: https://doi.org/10.1111/imj.12640
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2015-05-19 02:05:29

Last Modified: 2015-05-19 03:30:36